Caribou Biosciences, Inc. Accounts Payable
Caribou Biosciences, Inc. (CRBU) had Accounts Payable of $3.08 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $3.08M.
- 2026-03-31: Accounts Payable, Current $3.50M.
- 2025-12-31: Accounts Payable, Current $5.78M.
- 2025-09-30: Accounts Payable, Current $3.80M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $3.08M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.50M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $5.78M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.80M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $3.24M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.87M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.48M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.70M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.23M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $5.94M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $3.12M 10-K · filed 2025-03-10 |
| 2023-09-30 | $2.38M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $4.43M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.65M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.15M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.23M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $426.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.81M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.99M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.48M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.03M 10-Q · filed 2021-09-02 |
| 2020-12-31 | $2.60M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |